The Behavioral Economist
Behavioral finance, growth, small-cap, fund holdings

AtheroNova: Undervalued, Underappreciated, And Underestimated

Initially, the thought of establishing a long position in a developmental stage biopharmaceutical company, currently trading at a penny stock level, seems reckless. In the vast majority of instances, just considering such an investment could lead to an analyst being declared "audaciously hopeful" or "irresponsibly naïve". Such an opinion wouldn't be unreasonable. The list of biopharmaceutical entities that have failed to deliver on expectations and promises is not only long, but is adding new names to its collection on a near daily basis. Biotechnology is, after all, a high risk endeavor.

However, every once and a while a company long on potential and short on resources does something inexplicable; it succeeds. In recent times, the biotechnology company most revered...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details